Hypoglycemia is the key limiting step for optimizing glycemic control in older adults. Continuous glucose monitoring (CGM) technology has not been well-evaluated in insulin treated older patients with type 2 diabetes (T2D) .

Methods: This prospective observational cohort study assessed of glycemic control using the FreeStyle Libre Flash CGM in insulin treated older adult patients with T2D. Subjects >65 years with T2DM on insulin therapy and HbA1c between 7% and 9%, with or without oral agents, were identified from a public hospital and a private diabetes clinic and invited by phone to participate (n= 462) . Patients treated with GLP1 agonists; eGFR <30 ml/min; Hb <11g/dL; ALT> 3x ULN; glucocorticoid use in the previous 3 months, and active malignancy were excluded. Participants worn the CGM continuously during a 6-weeks study period. They returned to clinic every 2 weeks for CGM data downloaded and new CGM placement, assessment of glycemic control and hypoglycemia. The investigators adjusted insulin treatment at each visit as needed. The first 2 weeks of CGM was considered baseline point and the last 2 weeks was the endpoint. The differences on time in range (TIR 70-180, mg/dl) and time below range (TBR, < 70 mg/dl) was tested using the Wilcoxon Signed-rank test with p <0.05.

Results: A total of 125 patients were randomized and 49 patients completed the 6 weeks follow-up (women=53.9%; age=72.8 ± 5.0 years; BMI=28.3±3.6 Kg/m2; eGFR=62.4 ± 16.6; ml/min A1c=8.0 ± 0.57%; GMI=7.1 ± 0.8%. The patients had a median TIR of 65% (min= 7%, max= 94%) at the baseline and 68% (min= 4%; max= 97%) at the endpoint. The median TBR was 3% (min= 0%, max= 23%) at the baseline and 2% (min= 0%; max= 18%) at the end of study. The TBR was significantly reduced after 6 weeks of CGM (p<0.01) .

Conclusions: An individualized approach may be possible using FreeStyle Libre Flash CGM to avoid overtreatment and undertreatment of older adults with T2D. CGM is a useful tool to reduce hypoglycemia in insulin older adults with T2D.


S.A.O.Leite: None. M.Silva: None. A.C.R.Lavalle: None. M.Bastos: None. M.C.Bertogy: None. S.C.Vieira: None. G.E.Umpierrez: Research Support; AstraZeneca, Dexcom, Inc., Novo Nordisk.


Abbott DiabetesCare (ADC-OUS-IIS-19-47)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.